Karen Lundgren

3.8k total citations · 2 hit papers
38 papers, 3.1k citations indexed

About

Karen Lundgren is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Karen Lundgren has authored 38 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Karen Lundgren's work include Heat shock proteins research (19 papers), Cancer-related Molecular Pathways (6 papers) and Hepatitis C virus research (5 papers). Karen Lundgren is often cited by papers focused on Heat shock proteins research (19 papers), Cancer-related Molecular Pathways (6 papers) and Hepatitis C virus research (5 papers). Karen Lundgren collaborates with scholars based in United States, Canada and Germany. Karen Lundgren's co-authors include David Beach, Marc W. Kirschner, Robert Booher, Marlene Dembski, Nancy C. Walworth, Francis Burrows, Barbara A. Hamkalo, Marko Radic, Michael P. Rosenberg and Adeela Kamal and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Nature Genetics.

In The Last Decade

Karen Lundgren

38 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2

1991 592 citations Karen Lundgren, Nancy C. Walworth et al. Cell profile →
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins

2007 507 citations Chad A. Dickey, Adeela Kamal et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen Lundgren United States	22	2.4k	777	714	285	243	38	3.1k
Arianna Donella‐Deana Italy	33	2.2k 0.9×	447 0.6×	731 1.0×	312 1.1×	414 1.7×	91	3.8k
Ricardo M. Biondi Germany	31	3.4k 1.4×	554 0.7×	329 0.5×	172 0.6×	190 0.8×	79	4.1k
Colin M. House Australia	29	3.3k 1.3×	435 0.6×	532 0.7×	351 1.2×	341 1.4×	48	4.0k
Taebo Sim South Korea	31	3.5k 1.5×	609 0.8×	1.1k 1.5×	207 0.7×	353 1.5×	122	5.2k
Mario A. Pagano Italy	29	1.9k 0.8×	311 0.4×	368 0.5×	152 0.5×	206 0.8×	70	2.8k
Nicholas A. Morrice United Kingdom	36	3.3k 1.4×	653 0.8×	657 0.9×	316 1.1×	432 1.8×	64	4.2k
V. Kinzel Germany	31	2.6k 1.1×	571 0.7×	433 0.6×	181 0.6×	238 1.0×	126	3.5k
Weiru Wang United States	32	2.9k 1.2×	353 0.5×	705 1.0×	245 0.9×	157 0.6×	67	3.9k
Akira Asai Japan	33	1.8k 0.7×	337 0.4×	649 0.9×	294 1.0×	275 1.1×	132	3.0k

Countries citing papers authored by Karen Lundgren

Since Specialization

Citations

This map shows the geographic impact of Karen Lundgren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Lundgren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Lundgren more than expected).

Fields of papers citing papers by Karen Lundgren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Lundgren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Lundgren. The network helps show where Karen Lundgren may publish in the future.

Co-authorship network of co-authors of Karen Lundgren

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Lundgren. A scholar is included among the top collaborators of Karen Lundgren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Lundgren. Karen Lundgren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dowling, John P., Pavel A. Nikitin, Fang Shen, et al.. (2023). IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation. mAbs. 15(1). 2212673–2212673. 7 indexed citations

Lundgren, Karen, et al.. (2022). Treating people where they are: Nurse‐led micro‐elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada. Public Health Nursing. 39(5). 1009–1016. 8 indexed citations

Cunningham, Evan B., et al.. (2021). Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. International Journal of Drug Policy. 96. 103418–103418. 5 indexed citations

Card, Kiffer G., et al.. (2020). Exploring nurse‐led HIV Pre‐Exposure Prophylaxis in a community health care clinic. Public Health Nursing. 37(6). 871–879. 7 indexed citations

Cunningham, Evan B., et al.. (2019). Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada. International Journal of Drug Policy. 72. 106–113. 13 indexed citations

Bohonowych, Jessica, Shuping Peng, Udhayakumar Gopal, et al.. (2011). Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation. BMC Cancer. 11(1). 520–520. 25 indexed citations

Dakappagari, Naveen, Laura Neely, Shabnam Tangri, et al.. (2010). An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers. 15(1). 31–38. 49 indexed citations

Zhang, Hong, et al.. (2009). BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. International Journal of Cancer. 126(5). 1226–1234. 62 indexed citations

Yin, Xiaoying, Hong Zhang, Karen Lundgren, et al.. (2009). BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. International Journal of Cancer. 126(5). 1216–1225. 66 indexed citations

10.

Lundgren, Karen, Hong Zhang, Nanni Huser, et al.. (2009). BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Molecular Cancer Therapeutics. 8(4). 921–929. 140 indexed citations

11.

Moser, Christian, Sven A. Lang, Karen Lundgren, et al.. (2008). Targeting Hsp90 using EC154, a novel synthetic Hsp90 inhibitor, impairs multiple oncogenic signaling pathways in human gastric and pancreatic cancer cells and reduces tumor growth in vivo. Cancer Research. 68. 1181–1181. 1 indexed citations

12.

Dickey, Chad A., Adeela Kamal, Karen Lundgren, et al.. (2007). The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. Journal of Clinical Investigation. 117(3). 648–658. 507 indexed citations breakdown →

13.

Lundgren, Karen, Adeela Kamal, Rachel Lough, et al.. (2006). CNF2024 - The first clinical stage synthetic oral Hsp90 inhibitor. Cancer Research. 66. 1142–1142. 1 indexed citations

14.

Zhang, Hong, Laura Neely, Junhua Fan, et al.. (2006). Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Molecular Cancer Therapeutics. 5(5). 1256–1264. 52 indexed citations

15.

Hamlett, Jane, Stephen R. Pennington, Francis Burrows, et al.. (2005). The topoisomerase II–Hsp90 complex: A new chemotherapeutic target?. International Journal of Cancer. 118(11). 2685–2693. 32 indexed citations

16.

Chen, Ping, Chun Luo, Yali Deng, et al.. (2000). Implications for Chk1 Regulation: The 1.7 Å Crystal Structure of Human Cell Cycle Checkpoint Kinase Chk1. Cell. 100(6). 681–692. 164 indexed citations

17.

Hollander, M. Christine, M. Saeed Sheikh, Dmitry V. Bulavin, et al.. (1999). Genomic instability in Gadd45a-deficient mice. Nature Genetics. 23(2). 176–184. 436 indexed citations

18.

Lundgren, Karen, Sandra A. Allan, Tokio Tani, et al.. (1996). A connection between pre-mRNA splicing and the cell cycle in fission yeast: cdc28+ is allelic with prp8+ and encodes an RNA-dependent ATPase/helicase.. Molecular Biology of the Cell. 7(7). 1083–1094. 64 indexed citations

19.

Lundgren, Karen, Nancy C. Walworth, Robert Booher, et al.. (1991). mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell. 64(6). 1111–1122. 592 indexed citations breakdown →

20.

Hamkalo, Barbara A., Sandya Narayanswami, & Karen Lundgren. (1989). Localization of nucleic acid sequences by EM in situ hybridization using colloidal gold labels. American Journal of Anatomy. 185(2-3). 197–204. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact